271 completed, 68 terminated, 62 recruiting, 50 unknown. 509 Phase 2, 112 Phase 1, 14 Phase 3.
Follow Head and Neck Cancer: new trials by email Literature Review of Head and Neck Cancer trials Research Report on Head and Neck Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Ph2, Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy Colchicine, Placebo - Head and Neck Cancer | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 250 | 2027-03-01 | 2026-10-05 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse Placebo, Ketamine Topical - Head and Neck Cancer | Phase 2 | Not yet recruiting | University of Oklahoma | 62 | 2026-12-01 | 2026-10-16 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-04 | 2026-10-30 |
| Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients Bevonescein (ALM 488) Infusion - Head and Neck Disorder, Head and Neck Cancer | Phase 2 | Recruiting | Matthew Spector | 40 | 2026-10-18 | 2026-10-19 |
| Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC iparomlimab and tuvonralimab combined with cetuximab - Head and Neck Cancer | Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 26 | 2026-10-16 | 2026-10-20 |
| SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET [225Ac]Ac-FL-261 - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Recruiting | Full-Life Technologies UK Limited | 208 | 2026-10-01 | 2026-10-29 |
| Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab - Head and Neck Cancer, Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Mark Bernard | 35 | 2026-09-09 | 2026-10-14 |
| H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) XL092, Pembrolizumab - Oral Cavity Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 26 | 2026-09-01 | 2026-08-31 |
| A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED) Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease - Head and Neck Cancer, Head and Neck Squamous Cell Cancer | Phase 2 | Not yet recruiting | University of Maryland, Baltimore | 132 | 2026-09-01 | 2026-08-14 |
| Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma Becotatug Vedotin (MRG003), Pucotenlimab - Oral Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 32 | 2026-09-01 | 2026-08-17 |
| To Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies Boron Neutron Capture Therapy - Head and Neck Cancer | Phase 2 | Recruiting | Neuboron Bio-SciTech Co., Ltd. | 35 | 2026-08-31 | 2026-09-08 |
| Effects of Infusion Timing on Treatment Response in Solid Tumors PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-1 inhibitor monotherapy - 2 cycles before 12:00PM - Lung Cancer, Non-small Cell Lung Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 238 | 2026-08-03 | 2026-09-15 |
| Sancai Fengsui Decoction for RTOM: A Multicenter RCT Sancai Fengsui Decoction, Placebo Group - Radiation-Induced Oral Mucositis (RTOM), Head and Neck Cancer | Phase 2 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 126 | 2026-08-01 | 2026-07-09 |
| RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer RiMO-301, Pembrolizumab, Radiation - Head and Neck Cancer, Head Cancer | Phase 2 | Not yet recruiting | University of Illinois at Chicago | 20 | 2026-08-01 | 2026-07-29 |
| Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel - HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 70 | 2026-07-22 | 2026-06-04 |
| Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies camrelizumab with famitinib - Head and Neck Cancer | Phase 1 / Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 40 | 2026-07-01 | 2026-06-23 |
| Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Paclitaxel polymeric micelles - Head and Neck Cancer | Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 29 | 2026-07-01 | 2026-06-23 |
| Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma Becotatug Vedotin combined with Pucotenlimab, surgery - Head and Neck Cancer | Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 102 | 2026-06-16 | 2026-06-08 |
| A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment cemiplimab+fianlimab, Cemiplimab - Head and Neck Cancer | Phase 2 | Recruiting | University of Chicago | 68 | 2026-06-09 | 2026-07-16 |
Showing 20 of 509. Sign in to see all of them.
Head and Neck Neoplasms (509) · Squamous Cell Carcinoma of Head and Neck (177) · Lung Neoplasms (41) · Salivary Gland Neoplasms (39) · Carcinoma, Squamous Cell (38) · Carcinoma, Non-Small-Cell Lung (36) · Neoplasms (34) · Mouth Neoplasms (32) · Breast Neoplasms (31) · Ovarian Neoplasms (29) · Oropharyngeal Neoplasms (27) · Laryngeal Neoplasms (25) · Melanoma (23) · Neoplasm Metastasis (23) · Esophageal Neoplasms (21)
Neoplasms by Site (508) · Neoplasms (475) · Neoplasms by Histologic Type (266) · Neoplasms, Glandular and Epithelial (251) · Carcinoma (228) · Carcinoma, Squamous Cell (167) · Stomatognathic Diseases (103) · Respiratory Tract Diseases (93) · Mouth Diseases (85) · Respiratory Tract Neoplasms (85) · Digestive System Diseases (68) · Lung Diseases (63) · Thoracic Neoplasms (63) · Otorhinolaryngologic Diseases (61) · Gastrointestinal Diseases (59)
Cisplatin (108) · Radiotherapy (76) · Cetuximab (63) · Docetaxel (46) · Paclitaxel (44) · Carboplatin (41) · pembrolizumab (41) · Fluorouracil (35) · Radiotherapy, Intensity-Modulated (29) · Gemcitabine (16) · Drug Therapy (14) · Nivolumab (14) · Amifostine (13) · Erlotinib Hydrochloride (13) · Gefitinib (13)
Memorial Sloan Kettering Cancer Center (20) · M.D. Anderson Cancer Center (16) · University of Chicago (16) · Dana-Farber Cancer Institute (14) · National Cancer Institute (NCI) (14) · Radiation Therapy Oncology Group (11) · SWOG Cancer Research Network (10) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (9) · Eastern Cooperative Oncology Group (8) · UNC Lineberger Comprehensive Cancer Center (8) · University of Alabama at Birmingham (7) · Bristol-Myers Squibb (6) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · University of Texas Southwestern Medical Center (6)
United States (331) · Canada (39) · China (36) · France (32) · United Kingdom (27) · Belgium (26) · Spain (24) · Italy (17) · South Korea (17) · Netherlands (16) · Australia (14) · Taiwan (14) · Singapore (13) · Germany (10) · Switzerland (7)
Corey J. Langer, MD (5) · Athanassios Argiris, MD (4) · Jared Weiss, MD (4) · A. Dimitrios Colevas, MD (3) · Barbara A. Murphy, MD (3) · David G. Pfister, MD (3) · Everett Vokes, MD (3) · George H. Yoo, MD (3) · Mercedes Porosnicu, MD (3) · Merrill S. Kies, MD (3) · Nancy Lee, MD (3) · Omer Kucuk, MD (3) · Panayiotis Savvides, MD (3)
PMID 25057165, PMID 25081901, PMID 10444409, PMID 11323096, PMID 11712783, PMID 12676044, PMID 15571957, PMID 15625363, PMID 15641479, PMID 15659505, PMID 15735120, PMID 15860857, PMID 16116597, PMID 16470745, PMID 16522694, PMID 16760642, PMID 16779801, PMID 16823067, PMID 16849759, PMID 17509812, PMID 17530488, PMID 17538162, PMID 17538163, PMID 17545536, PMID 17761982, PMID 17938330, PMID 17942826, PMID 17947728, PMID 17985985, PMID 18270337, PMID 18381950, PMID 18484593, PMID 18628464, PMID 18640496, PMID 18819792, PMID 19097774, PMID 19265494, PMID 19288572, PMID 19393114, PMID 19540060, PMID 19557750, PMID 19564532, PMID 19634157, PMID 19634161, PMID 19720915, PMID 19770418, PMID 19850643, PMID 19917840, PMID 19924794, PMID 20378262
U10CA032102 (10), P30CA006516 (9), 2023 (5), P30CA043703 (4), 2017 (3), P30CA006973 (3), P30CA012197 (3), P30CA022453 (3), U10CA021115 (3), 2016 (2), P30CA006927 (2), P30CA016672 (2), P50CA096784 (2), 2015 (1), 2019 (1)